Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

M 254

Drug Profile

M 254

Alternative Names: hsIgG; Hypersialylated IgG; Hypersialylated immunoglobulin; M254

Latest Information Update: 28 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Virdante Pharmaceuticals
  • Developer Momenta Pharmaceuticals
  • Class Anti-inflammatories; Immunoglobulin isotypes; Immunotherapies; Recombinant proteins; Sialic acids
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Idiopathic thrombocytopenic purpura
  • No development reported Chronic inflammatory demyelinating polyradiculoneuropathy

Most Recent Events

  • 28 Feb 2023 No recent reports of development identified for phase-I development in Chronic inflammatory demyelinating polyradiculoneuropathy in USA (Parenteral)
  • 01 Jun 2022 Takeda in-licenses M 254 from Momenta Pharmaceuticals
  • 02 Aug 2021 Momenta Pharmaceuticals terminates a phase I/II trial in Idiopathic thrombocytopenic purpura in Belgium, Hungary, Italy, Netherlands, Poland, Spain, USA, based on sponsor decision (IV) after December 2018 (NCT03866577) (EudraCT2018-003534-32)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top